ArticleJournal of inflammation (London, England)2016
Phenotypic analysis of peripheral B cell populations during Mycobacterium tuberculosis infection and disease.
Article in Journal of inflammation (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Antibodies in tuberculosis: functional capacity as key determinant.Infection and immunity · 2026Review
- Peripheral blood B-cell compartment dysregulation in multidrug-resistant tuberculosis is associated with reduced circulating marginal zone-like B cells.Frontiers in immunology · 2026Article
- Splenic marginal zone B cells restrict Mycobacterium tuberculosis infection by shaping the cytokine pattern and cell-mediated immunity.Cell reports · 2024Article
- B cell heterogeneity in human tuberculosis highlights compartment-specific phenotype and functional roles.Communications biology · 2024Article
- Tuberculosis and COVID-19 Dually Affect Human Th17 Cell Immune Response.Biomedicines · 2023Review
- Antigen-specific B cells direct T follicular-like helper cells into lymphoid follicles to mediate Mycobacterium tuberculosis control.Nature immunology · 2023Article
- Phenotypic characterization of Peripheral B cells in Mycobacterium tuberculosis infection and disease in Addis Ababa, Ethiopia.Tuberculosis (Edinburgh, Scotland) · 2023Article
- Antigen-specific cytokine profiles for pulmonaryFrontiers in immunology · 2023Article
- Mechanisms of lung damage in tuberculosis: implications for chronic obstructive pulmonary disease.Frontiers in cellular and infection microbiology · 2023Review
- Active tuberculosis patients have high systemic IgG levels and B-cell fingerprinting, characterized by a reduced capacity to produce IFN-γ or IL-10 as a response toFrontiers in immunology · 2023Article
- Impact ofCells · 2022Article
- Distinct and shared B cell responses of tuberculosis patients and their household contacts.PloS one · 2022Article
- Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis.Frontiers in immunology · 2022Review
- B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis.Frontiers in immunology · 2021Review
- Immunoglobulin profile and B-cell frequencies are altered with changes in the cellular microenvironment independent of the stimulation conditions.Immunity, inflammation and disease · 2020Article
- Mycobacterium tuberculosis-specific plasmablast levels are differentially modulated in tuberculosis infection and disease.Tuberculosis (Edinburgh, Scotland) · 2020Article
- Thinking Outside the Box: Innate- and B Cell-Memory Responses as Novel Protective Mechanisms Against Tuberculosis.Frontiers in immunology · 2020Review
- Diagnosis for Latent Tuberculosis Infection: New Alternatives.Frontiers in immunology · 2020Review
- Effect of binding immunoglobulin protein on induction of regulatory B cells with killer phenotype during inflammation and disease.Future science OA · 2019Review
- Both B-1a and B-1b cells exposed to Mycobacterium tuberculosis lipids differentiate into IgM antibody-secreting cells.Immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycobacterium tuberculosis (Mtb) remains an unresolved threat resulting in great annual loss of life. The role of B cells during the protective immunity to Mtb is still unclear. B cells have been described as effector cells in addition to their role as antibody producing cells during disease. Here we aim to identify and characterize the frequency of peripheral B-cell subpopulations during active Tuberculosis and over treatment response. Analysis were done for both class switched (CS) and non-class switched (NCS) phenotypes.
methodsWe recruited participants with active untreated pulmonary Tuberculosis, other lung diseases and healthy community controls. All groups were followed up for one week from recruitment and the TB cases till the end of treatment (month 6).
resultsPeripheral blood samples were collected, stained with monoclonal antibodies to CD19(+) cells, Immunoglobulin (Ig) M, plasma cells (CD 138(+)), marker of memory (CD27(+)), immune activation (CD23(+)) and acquired on a flow cytometer. Circulating Marginal zone B cells (CD19(+)IgM(+)CD23(-)CD27(+)) and memory phenotypes are able to distinguish between TB diagnosis and end of treatment. The frequency of mature B cells from TB cases are lower than that of other-lung diseases at diagnosis. A subpopulation of activated memory B cells (CD19(+)IgM(+)CD23(+)CD27(+)) cells are present at the end of TB treatment.
conclusionsThis study identified distinctive B cell subpopulations present during active TB disease and other lung disease conditions. These cell populations warrants further examination in larger studies as it may be informative as cell markers or as effectors/regulators in TB disease or TB treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.